Clinical Trials - What to Expect in 2024 - A Preview of Trials Planned to Initiate and Estimated to Complete

Clinical Trials - What to Expect in 2024 - A Preview of Trials Planned to Initiate and Estimated to Complete

Summary

This report provides a preview of clinical trials that are planned to be initiated and projected to be completed in 2024.

Scope

• The clinical trials data used for these analyses were extracted from GlobalData’s Clinical Trials Database. The data included planned clinical trials with a start date from January 1 to December 31, 2024, captured in the database as of December 15, 2023. The planned trials were analyzed and segmented by phase, single versus multinational trials, geography, sponsor type (industry versus non-industry), therapy area, indication, top sponsors, drug type, and DCT use. Clinical trials with an ongoing or planned status with an end date between January 1 and December 31, 2024, were also examined. The trials that are estimated to be completed in 2024 were split by phase, status, indication, sponsor type, top sponsors, geography and DCT use. In this report, a small number of Phase 0, Phase I/II, Phase II/III, and Phase III/IV trials were combined with Phase I, Phase II, Phase III, and Phase IV trials, respectively.

Reasons to Buy

• Understand the planned trials landscape and trends for 2024
• Provide early insight for studies expected to be completed in 2024
• The 2024 trends of DCTs in both planned trials and trials to be completed